Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first 24 hours after surgery, a failure to successfully orally re-feed a subject is defined as presentation with emesis, requiring a reversal of diet, or the placement of a nasogastric tube on first postoperative day or later.
The device is considered non-significant risk (NSR). The device does not inform medical decisions in this study. Researchers will be blinded to results of the device during this study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PrevisEA device | Experimental | The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PrevisEA device | Device | The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants. |
| Measure | Description | Time Frame |
|---|---|---|
| Performance of the PrevisEA device | The performance (accuracy) of the device in predicting development of GII will be assessed through evaluation of the primary outcome measures of sensitivity and specificity for the device. | 1-14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Positive predictive value (PPV) | Measures will be analyzed by using available data only | 1-14 days |
| Negative predictive value (NPV) | Measures will be analyzed by using available data only |
Not provided
Inclusion Criteria:
Age ≥ 18 and ≤ 90 years
Patient undergoing elective intestinal resection surgery including open, laparoscopic, robotic, or hand-assist technique for:
Exclusion Criteria:
Allergies to any of the device components (i.e., adhesive)
Inability to have prototype device applied to their abdominal wall due to disease conditions or surgical alterations(e.g., fistulas, stomas, drains, etc.)
Patients undergoing:
Patients with preoperative evidence of an anastomotic leak, deep wound infection, organ space infection, or urinary tract infection
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Entac Medical Inc. | Contact | 845-773-8473 | previsea-001@clinicalresearchstrategies.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Adventist Health System/Sunbelt, Inc. d/b/a AdventHealth Orlando | Recruiting | Orlando | Florida | 32803 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014839 | Vomiting |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 1-14 days |
| Overall percent agreement (OPA) | Measures will be analyzed by using available data only | 1-14 days |
| Northwestern University | Recruiting | Chicago | Illinois | 60611 | United States |
|
| Spectrum Health Blodgett Hospital | Recruiting | Grand Rapids | Michigan | 49503 | United States |
|
| University of Minnesota | Recruiting | Minneapolis | Minnesota | 55414 | United States |
|
| Mayo Clinic | Recruiting | Rochester | Minnesota | 55905 | United States |
|
| The University of North Carolina at Chapel Hill | Recruiting | Chapel Hill | North Carolina | 27599-1350 | United States |
|
| The Cleveland Clinic Foundation | Recruiting | Cleveland | Ohio | 44195 | United States |
|
| Oregon Health and Science University | Recruiting | Portland | Oregon | 97239 | United States |
|